Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Public ClinicalTrials.gov record NCT04502030. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT04502030
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Octapharma
- Industry
- Enrollment
- 247 participants
Conditions and interventions
Interventions
- Panzyga Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2020
- Primary completion
- Sep 18, 2025
- Completion
- Sep 18, 2025
- Last update posted
- Oct 2, 2025
2020 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Octapharma Research Site | St. Petersburg | Florida | 33709 | — |
| Octapharma Research Site | Columbus | Georgia | 31904 | — |
| Octapharma Research Site | Macon | Georgia | 31201 | — |
| Octapharma Research Site | New Orleans | Louisiana | 70112 | — |
| Octapharma Research Site | Baltimore | Maryland | 21201 | — |
| Octapharma Research Site | Baltimore | Maryland | 21205 | — |
| Octapharma Research Site | Detroit | Michigan | 48093 | — |
| Octapharma Research Site | Rochester | Minnesota | 55902 | — |
| Octapharma Research Site | Buffalo | New York | 14260 | — |
| Octapharma Research Site | New York | New York | 10032 | — |
| Octapharma Research Site | New York | New York | 10065 | — |
| Octapharma Research Site | Shirley | New York | 11967 | — |
| Octapharma Research Site | Durham | North Carolina | 27710 | — |
| Octapharma Research Site | Charleston | South Carolina | 29414 | — |
| Octapharma Research Site | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04502030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04502030 live on ClinicalTrials.gov.